CLDX ▲ +0.1% - Celldex Therapeutics, Inc. $CLDX Morgan Stanley raised the firm's price target on Celldex to $57 from $50 and keeps an Overweight rating on the shares. Barzolvolimab demonstrated best-in-disease efficacy in EMBARQ-CSU, while its safety proved to be "the primary source of debate," the analyst tells investors. Management sees a black box warning as unlikely, says the analyst, who believes the safety profile remains "manageable" and continues to see "a blockbuster opportunity in chronic urticaria." Morgan Stanley raised its price target on Celldex to $57 from $50 and maintained an Overweight rating, citing best-in-disease efficacy for barzolvolimab in the EMBARQ-CSU trial and a manageable safety profile that the analyst believes is unlikely to trigger a black box warning. The analyst sees blockbuster potential for the drug in chronic urticaria, though safety remains a point of discussion among investors. 23-SEP-2026 09:13 AM ET